Controlling the kinetics of transgene expression by plasmid design

被引:30
作者
Yew, NS [1 ]
机构
[1] Genzyme Corp, Framingham, MA 01701 USA
关键词
plasmid DNA; promoter; gene expression; synthetic vectors; CpG motifs; gene regulation; small molecule drugs;
D O I
10.1016/j.addr.2004.12.009
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
While a vast array of liposomes, peptides, and molecular conjugates have been evaluated for nonviral gene transfer, the entity containing the actual gene itself is almost always a plasmid. The layout of most plasmid DNA (pDNA) vectors is usually quite simple, consisting of a promoter, transgene, polyadenylation signal, and a backbone that permits propagation of the plasmid in bacteria. Additional sequence elements and modifications can be incorporated to influence the stability of gene expression and retention of the pDNA molecule in a given tissue. This review describes the different choices that can be made when designing a pDNA vector for transient, sustained, or regulated expression. The choice of promoter is a major determinant governing the kinetics of expression, but other factors, such as CpG content and the topological form of the pDNA are also influential. Vectors can also be designed to respond to the local environment of a given cell or tissue, or engineered to respond to a small molecule drug. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:769 / 780
页数:12
相关论文
共 73 条
[1]   Ligand-dependent regulation of vascular endothelial growth factor and erythropoietin expression by a plasmid-based autoinducible GeneSwitch system [J].
Abruzzese, RV ;
Godin, D ;
Mehta, V ;
Perrard, JL ;
French, M ;
Nelson, W ;
Howell, G ;
Coleman, M ;
O'Malley, BW ;
Nordstrom, JL .
MOLECULAR THERAPY, 2000, 2 (03) :276-287
[2]   Ligand-dependent regulation of plasmid-based transgene expression in vivo [J].
Abruzzese, RV ;
Godin, D ;
Burcin, M ;
Mehta, V ;
French, M ;
Li, YH ;
O'Malley, BW ;
Nordstrom, JL .
HUMAN GENE THERAPY, 1999, 10 (09) :1499-1507
[3]   Long-term therapeutic levels of human alpha-1 antitrypsin in plasma after hydrodynamic injection of nonviral DNA [J].
Aliño, SF ;
Crespo, A ;
Dasí, F .
GENE THERAPY, 2003, 10 (19) :1672-1679
[4]   Tet repressor-based system for regulated gene expression in eukaryotic cells: Principles and advances [J].
Baron, U ;
Bujard, H .
APPLICATIONS OF CHIMERIC GENES AND HYBRID PROTEINS PT B: CELL BIOLOGY AND PHYSIOLOGY, 2000, 327 :401-421
[5]   An adenoviral vector regulated by hypoxia for the treatment of ischaemic disease and cancer [J].
Binley, K ;
Iqball, S ;
Kingsman, A ;
Kingsman, S ;
Naylor, S .
GENE THERAPY, 1999, 6 (10) :1721-1727
[6]   Hypoxia-mediated tumour targeting [J].
Binley, K ;
Askham, Z ;
Martin, L ;
Spearman, H ;
Day, D ;
Kingsman, S ;
Naylor, S .
GENE THERAPY, 2003, 10 (07) :540-549
[7]   Long-term reversal of chronic anemia using a hypoxia-regulated erythropoietin gene therapy [J].
Binley, K ;
Askham, Z ;
Iqball, S ;
Spearman, H ;
Martin, L ;
de Alwis, M ;
Thrasher, AJ ;
Ali, RR ;
Maxwell, PH ;
Kingsman, S ;
Naylor, S .
BLOOD, 2002, 100 (07) :2406-2413
[8]   Highly suppressible expression of single-chain interleukin-12 by doxycycline following adenoviral infection with a single-vector tet-regulatory system [J].
Block, A ;
Puls, F ;
Müller, J ;
Milasinovic, D ;
Igelmann, D ;
Schäfer, P ;
Kupfermann, N ;
Schmoldt, A ;
Ameis, D ;
Greten, H .
JOURNAL OF GENE MEDICINE, 2003, 5 (03) :190-200
[9]  
Borrelli MJ, 2001, CANCER RES, V61, P1113
[10]   A VERY STRONG ENHANCER IS LOCATED UPSTREAM OF AN IMMEDIATE EARLY GENE OF HUMAN CYTOMEGALO-VIRUS [J].
BOSHART, M ;
WEBER, F ;
JAHN, G ;
DORSCHHASLER, K ;
FLECKENSTEIN, B ;
SCHAFFNER, W .
CELL, 1985, 41 (02) :521-530